INSULIN DEGLUDEC/INSULIN ASPART (IDEGASP) PRODUCES A DOSE-PROPORTIONAL GLUCOSE-LOWERING EFFECT IN SUBJECTS WITH TYPE 1 DIABETES

被引：0
|
作者：
Heise, T. [1 ]
Nosek, L. [1 ]
Coester, H. [1 ]
Klein, O. [1 ]
Roepstorff, C. [2 ]
Svendsen, A. L. [2 ]
Haahr, H. [2 ]
机构：
[1] Profil Inst Stoffwechselforsch, Neuss, Germany
[2] Novo Nordisk AS, Soborg, Denmark
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2014年 / 106卷
关键词：
D O I：
10.1016/S0168-8227(14)70536-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO242
引用
收藏
页码：S173 / S174
页数：2
相关论文
共 50 条
  • [1] Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus
    Heise, T.
    Nosek, L.
    Klein, O.
    Coester, H.
    Svendsen, A. L.
    Haahr, H.
    [J]. DIABETES OBESITY & METABOLISM, 2015, 17 (07): : 659 - 664
  • [2] IDegAsp produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes
    Nosek, L.
    Heise, T.
    Klein, O.
    Coester, H. -V.
    Roepstorff, C.
    Svendsen, A.
    Haahr, H.
    [J]. DIABETOLOGIA, 2013, 56 : S418 - S419
  • [3] IDegAsp Produces Dose-Proportional Glucose-Lowering Effect in Subjects With Type 1 Diabetes
    Heise, Tim
    Nosek, Leszek
    Klein, Oliver
    Coester, Hans-Veit
    Roepstorff, Carsten
    Svendsen, Anne Louise
    Haahr, Hanne
    [J]. DIABETES, 2013, 62 : A241 - A241
  • [4] Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus
    Tim Heise
    Leszek Nosek
    Carsten Roepstorff
    Suresh Chenji
    Oliver Klein
    Hanne Haahr
    [J]. Diabetes Therapy, 2014, 5 : 255 - 265
  • [5] Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus
    Heise, Tim
    Nosek, Leszek
    Roepstorff, Carsten
    Chenji, Suresh
    Klein, Oliver
    Haahr, Hanne
    [J]. DIABETES THERAPY, 2014, 5 (01) : 255 - 265
  • [6] Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects
    Haahr, Hanne
    Sasaki, Tomio
    Bardtrum, Lars
    Ikushima, Ippei
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2016, 7 (04) : 574 - 580
  • [7] GREATER EARLY INSULIN EXPOSURE AND GLUCOSE-LOWERING WITH FASTER-ACTING INSULIN ASPART VS INSULIN ASPART IN JAPANESE SUBJECTS WITH TYPE 1 DIABETES
    Shiramoto, M.
    Nishida, T.
    Hansen, A. K.
    Haahr, H.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A118 - A119
  • [8] Faster Onset and Greater Early Exposure and Glucose-Lowering Effect with Faster-Acting Insulin Aspart vs. Insulin Aspart: A Pooled Analysis in Subjects with Type 1 Diabetes
    Heise, Tim
    Pieber, Thomas R.
    Danne, Thomas
    Erichsen, Lars
    Haahr, Hanne
    [J]. DIABETES, 2016, 65 : A239 - A239
  • [9] Higher early insulin exposure and greater early glucose-lowering effect with faster-acting insulin aspart vs insulin aspart in Japanese patients with type 1 diabetes
    Shiramoto, M.
    Nishida, T.
    Hansen, A.
    Haahr, H.
    [J]. DIABETOLOGIA, 2015, 58 : S403 - S403
  • [10] IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, in type 2 diabetes: comparison with biphasic insulin aspart 30
    Vaag, A.
    Leiter, L. A.
    Franek, E.
    Weng, J.
    Damci, T.
    Munoz Torres, M.
    Donnet, J. -P.
    Endahl, L.
    Skjoth, T.
    Niskanen, L.
    [J]. DIABETOLOGIA, 2011, 54 : S423 - S423
12345